Differential neutralizing antibody responses elicited by CoronaVac and BNT162b2 against SARS-CoV-2 Lambda in Chile

  1. Mónica L. Acevedo
  2. Aracelly Gaete-Argel
  3. Luis Alonso-Palomares
  4. Marco Montes de Oca
  5. Andrés Bustamante
  6. Aldo Gaggero
  7. Fabio Paredes
  8. Claudia P. Cortes
  9. Sergio Pantano
  10. Constanza Martínez-Valdebenito
  11. Jenniffer Angulo
  12. Nicole Le Corre
  13. Marcela Ferrés
  14. Marcelo A. Navarrete
  15. Fernando Valiente-Echeverría
  16. Ricardo Soto-Rifo

Reviewed by

Read the full article See related articles

Listed in

Log in to save this article

Abstract

No abstract available

Article activity feed

  1. Version published to 10.1038/s41564-022-01092-1
  2. Version published to 10.21203/rs.3.rs-782704/v1 on Research Square
  3. Rapid Reviews Infectious Diseases

    Orson Mestanza

    Review 2: "Infectivity and immune escape of the new SARS-CoV-2 variant of interest Lambda"

    This preprint describes gain-of-function properties for mutations defining the Lambda variant and the effectiveness of the CoronaVac vaccine against this variant. Reviewers consider the data reliable and require minor revision to clarify methodology.

  4. Rapid Reviews Infectious Diseases

    Alex Sigal

    Review 1: "Infectivity and immune escape of the new SARS-CoV-2 variant of interest Lambda"

    This preprint describes gain-of-function properties for mutations defining the Lambda variant and the effectiveness of the CoronaVac vaccine against this variant. Reviewers consider the data reliable and require minor revision to clarify methodology.

  6. ScreenIT

    SciScore for 10.1101/2021.06.28.21259673: (What is this?)

    Please note, not all rigor criteria are appropriate for all manuscripts.

    Table 1: Rigor

    EthicsConsent: All participants signed an informed consent before any study procedure was undertaken.
    IRB: Ethical approval: The study protocol was approved by the Ethics Committee of the Faculty of Medicine at Universidad de Chile (Projects N° 0361-2021 and N° 096-2020) and Clínica Santa Maria (Project N°132604-21).
    Sex as a biological variablenot detected.
    Randomizationnot detected.
    Blindingnot detected.
    Power Analysisnot detected.
    Cell Line Authenticationnot detected.

    Table 2: Resources

    Experimental Models: Cell Lines
    SentencesResources
    Different amounts of pseudotyped viruses (as determined by the levels of the HIV-1 p24 protein) were used to infect HEK-ACE2 cells and 48 hours later, firefly luciferase activity was measured using the Luciferase Assay Reagent (Promega) in a Glomax 96 Microplate luminometer (Promega).
    HEK-ACE2
    suggested: None
    HEK293T cells (not expressing ACE2) incubated with the pseudotyped virus (lineage A) were used as a negative control.
    HEK293T
    suggested: CCLV Cat# CCLV-RIE 1018, RRID:CVCL_0063)
    Recombinant DNA
    SentencesResources
    Briefly, HIV-1-based SARS-CoV-2 pseudotypes were produced in HEK293T cells by transfecting the pNL4.3-ΔEnv-Luc together with the corresponding pCDNA-SARS-CoV-2 Spike coding vector in a 1:1 molar ratio.
    pNL4.3-ΔEnv-Luc
    suggested: None
    pCDNA-SARS-CoV-2
    suggested: None
    Software and Algorithms
    SentencesResources
    The percentage of neutralization for each dilution was calculated and the ID50 of each sample was calculated using GraphPad Prism version 9.0.1.
    GraphPad Prism
    suggested: (GraphPad Prism, RRID:SCR_002798)

    Results from OddPub: Thank you for sharing your code and data.

    Results from LimitationRecognizer: An explicit section about the limitations of the techniques employed in this study was not found. We encourage authors to address study limitations.

    Results from TrialIdentifier: No clinical trial numbers were referenced.

    Results from Barzooka: We did not find any issues relating to the usage of bar graphs.

    Results from JetFighter: We did not find any issues relating to colormaps.

    Results from rtransparent:
    • Thank you for including a conflict of interest statement. Authors are encouraged to include this statement when submitting to a journal.
    • Thank you for including a funding statement. Authors are encouraged to include this statement when submitting to a journal.
    • No protocol registration statement was detected.

    Results from scite Reference Check: We found no unreliable references.

    About SciScore

    SciScore is an automated tool that is designed to assist expert reviewers by finding and presenting formulaic information scattered throughout a paper in a standard, easy to digest format. SciScore checks for the presence and correctness of RRIDs (research resource identifiers), and for rigor criteria such as sex and investigator blinding. For details on the theoretical underpinning of rigor criteria and the tools shown here, including references cited, please follow this link.

  7. Version published to 10.1101/2021.06.28.21259673v1 on medRxiv